Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers (Q56900377)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers	article

Statements

scholarly article

0 references

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers (English)

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Ahmad A Tarhini

1

0 references

John M Kirkwood

2

0 references

language of work or name

0 references

publication date

October 2008

0 references

Expert Opinion on Biological Therapy

0 references

8

0 references

10

0 references

1583-93

0 references

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Cutaneous melanoma: available therapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Recent progress in the management of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

CD28/B7 system of T cell costimulation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

The Emerging Role of CTLA-4 as an Immune Attenuator

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

The role of CTLA-4 in the regulation of T cell immune responses.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

The art of antibody process development

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Metabolic properties of IgG subclasses in man

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.10.1583

21 January 2018

Identifiers

10.1517/14712598.8.10.1583

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56900377&oldid=1880778062"